162 related articles for article (PubMed ID: 31356752)
1. Detecting Functional and Accessible Folate Receptor Expression in Cancer and Polycystic Kidneys.
Chu H; Shillingford JM; Reddy JA; Westrick E; Nelson M; Wang EZ; Parker N; Felten AE; Vaughn JF; Xu LC; Lu YJ; Vlahov IR; Leamon CP
Mol Pharm; 2019 Sep; 16(9):3985-3995. PubMed ID: 31356752
[TBL] [Abstract][Full Text] [Related]
2. Folate Receptor α-Targeted
Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y
Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274
[TBL] [Abstract][Full Text] [Related]
3. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
4. Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17.
Tummers QR; Hoogstins CE; Gaarenstroom KN; de Kroon CD; van Poelgeest MI; Vuyk J; Bosse T; Smit VT; van de Velde CJ; Cohen AF; Low PS; Burggraaf J; Vahrmeijer AL
Oncotarget; 2016 May; 7(22):32144-55. PubMed ID: 27014973
[TBL] [Abstract][Full Text] [Related]
5. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
[TBL] [Abstract][Full Text] [Related]
6. Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.
Azaïs H; Queniat G; Bonner C; Kerdraon O; Tardivel M; Jetpisbayeva G; Frochot C; Betrouni N; Collinet P; Mordon S
Int J Gynecol Cancer; 2015 Sep; 25(7):1194-200. PubMed ID: 26244757
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy.
Leamon CP; Reddy JA; Vlahov IR; Dorton R; Bloomfield A; Vetzel M; Klein PJ; Westrick E; Xu LC; Wang Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1151-1160. PubMed ID: 28451831
[TBL] [Abstract][Full Text] [Related]
8. Folate-dactolisib conjugates for targeting tubular cells in polycystic kidneys.
Shi H; Leonhard WN; Sijbrandi NJ; van Steenbergen MJ; Fens MHAM; van de Dikkenberg JB; Toraño JS; Peters DJM; Hennink WE; Kok RJ
J Control Release; 2019 Jan; 293():113-125. PubMed ID: 30472374
[TBL] [Abstract][Full Text] [Related]
9. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.
Saito S; Koya Y; Kajiyama H; Yamashita M; Kikkawa F; Nawa A
Cancer Sci; 2020 May; 111(5):1794-1804. PubMed ID: 32154964
[TBL] [Abstract][Full Text] [Related]
10. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
11. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
12. Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.
Cheung A; Opzoomer J; Ilieva KM; Gazinska P; Hoffmann RM; Mirza H; Marlow R; Francesch-Domenech E; Fittall M; Dominguez Rodriguez D; Clifford A; Badder L; Patel N; Mele S; Pellizzari G; Bax HJ; Crescioli S; Petranyi G; Larcombe-Young D; Josephs DH; Canevari S; Figini M; Pinder S; Nestle FO; Gillett C; Spicer JF; Grigoriadis A; Tutt ANJ; Karagiannis SN
Clin Cancer Res; 2018 Oct; 24(20):5098-5111. PubMed ID: 30068707
[No Abstract] [Full Text] [Related]
13. Exploiting the folate receptor α in oncology.
Scaranti M; Cojocaru E; Banerjee S; Banerji U
Nat Rev Clin Oncol; 2020 Jun; 17(6):349-359. PubMed ID: 32152484
[TBL] [Abstract][Full Text] [Related]
14. SERS nanotags for folate receptor α detection at the single cell level: discrimination of overexpressing cells and potential for live cell applications.
Verdin A; Sloan-Dennison S; Malherbe C; Graham D; Eppe G
Analyst; 2022 Jul; 147(14):3328-3339. PubMed ID: 35762669
[TBL] [Abstract][Full Text] [Related]
15.
Altwerger G; Bonazzoli E; Bellone S; Egawa-Takata T; Menderes G; Pettinella F; Bianchi A; Riccio F; Feinberg J; Zammataro L; Han C; Yadav G; Dugan K; Morneault A; Ponte JF; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Mol Cancer Ther; 2018 May; 17(5):1003-1011. PubMed ID: 29440294
[TBL] [Abstract][Full Text] [Related]
16. Structural and functional insights on folate receptor α (FRα) by homology modeling, ligand docking and molecular dynamics.
Della-Longa S; Arcovito A
J Mol Graph Model; 2013 Jul; 44():197-207. PubMed ID: 23880302
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.
Azaïs H; Schmitt C; Tardivel M; Kerdraon O; Stallivieri A; Frochot C; Betrouni N; Collinet P; Mordon S
Photodiagnosis Photodyn Ther; 2016 Mar; 13():130-138. PubMed ID: 26200606
[TBL] [Abstract][Full Text] [Related]
18. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications.
Hulin-Curtis SL; Davies JA; Nestić D; Bates EA; Baker AT; Cunliffe TG; Majhen D; Chester JD; Parker AL
Cancer Gene Ther; 2020 Nov; 27(10-11):785-798. PubMed ID: 31902944
[TBL] [Abstract][Full Text] [Related]
19. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-
Hou Z; Gattoc L; O'Connor C; Yang S; Wallace-Povirk A; George C; Orr S; Polin L; White K; Kushner J; Morris RT; Gangjee A; Matherly LH
Mol Cancer Ther; 2017 May; 16(5):819-830. PubMed ID: 28138029
[TBL] [Abstract][Full Text] [Related]
20. Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship.
Leamon CP; Vlahov IR; Reddy JA; Vetzel M; Santhapuram HK; You F; Bloomfield A; Dorton R; Nelson M; Kleindl P; Vaughn JF; Westrick E
Bioconjug Chem; 2014 Mar; 25(3):560-8. PubMed ID: 24564229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]